Nokea
The FDA issued a safety announcement regarding the use of erythropoiesis-stimulating agents (ESAs) in 2010 with the recommendation that:
- A. ESAs no longer be prescribed to patients with chronic renal failure
- B. The risk of tumor development be explained to cancer patients on ESA therapy
- C. Patients should no longer receive ESA therapy to prepare for allogenic transfusions
- D. ESAs be prescribed only to patients staying
Correct Answer: B
Rationale: The 2010 FDA warning highlighted tumor progression risks in cancer patients on ESAs; renal use continues with caution.
You may also like to solve these questions
Indirect costs associated with drug therapy include:
- A. The cost of diagnostic tests to monitor therapeutic levels
- B. Health-care provider time to prescribe and educate the patient
- C. Child-care expenses incurred while receiving therapy
- D. Loss of wages while undergoing drug therapy
Correct Answer: D
Rationale: Indirect costs include societal impacts like lost wages due to treatment.
Which of the following statement is not correct for insulin medications:
- A. Effective for treatment of diabetes type I
- B. Effective for treament of diabetes type II
- C. Is for parenteral use
- D. Is for intravenous use only
Correct Answer: D
Rationale: Insulin is not exclusively for IV use; it's typically subcutaneous, though IV is used in emergencies.
The nurse is assessing a client with diabetes who reports several hypoglycemic episodes during the past 3 weeks. What assessment question best addresses a potential causative factor?
- A. Do you ever take St. John's wort?'
- B. Have you used any recreational drugs in the past few weeks?'
Correct Answer: A
Rationale: St. John's wort can affect glucose metabolism and drug interactions, potentially causing hypoglycemia in diabetics.
Irreversible interaction of an antagonist with a receptor is due to:
- A. Ionic bonds
- B. Hydrogen bonds
- C. Covalent bonds
- D. All of the above
Correct Answer: C
Rationale: Irreversible antagonism typically involves covalent bonding, making it permanent.
A nurse is assisting with caring for a client with cancer who is receiving cisplatin. Select the adverse effects that the nurse monitors for that are associated with this medication. (Select one that does not apply.)
- A. Tinnitus
- B. Ototoxicity
- C. Hyperkalemia
- D. Hypomagnesemia
Correct Answer: C
Rationale: Cisplatin is an alkylating medication. Alkylating medications are cell cycle phase-nonspecific medications that affect the synthesis of DNA by causing the cross-linking of DNA to inhibit cell reproduction. Cisplatin may cause ototoxicity, tinnitus, hypokalemia, hypocalcemia, hypomagnesemia, and nephrotoxicity. Amifostine (Ethyol) may be administered before cisplatin to reduce the potential for renal toxicity. Correct answers include: 1 (Tinnitus), 2 (Ototoxicity), 5 (Nephrotoxicity), 6 (Hypomagnesemia).